Literature DB >> 30072541

Tuberculosis after a borderline QuantiFERON result during screening before infliximab.

Jonathan W Uzorka1, Nathalie M Delfos2, Anne M C Witte3, Henk Scheper1, Dick van Soolingen4, Sandra M Arend1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30072541     DOI： 10.1183/13993003.00913-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Trends in diagnostic methods and treatment of latent tuberculosis infection in a tertiary care center from 2000 to 2017.

Authors:  Jonathan W Uzorka; Dinah L Duinkerk; Lucia J M Kroft; Jaap A Bakker; Rajen S R S Ramai; Tom H M Ottenhoff; Sandra M Arend
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-02-20       Impact factor: 3.267

2.  Abnormalities suggestive of latent tuberculosis infection on chest radiography; how specific are they?

Authors:  Jonathan W Uzorka; Lucia J M Kroft; Jaap A Bakker; Erik W van Zwet; Erik Huisman; Corine Prins; Cornelis J van der Zwan; Tom H M Ottenhoff; Sandra M Arend
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-01-25

3.  Biomarkers to identify Mycobacterium tuberculosis infection among borderline QuantiFERON results.

Authors:  Jonathan W Uzorka; Jaap A Bakker; Krista E van Meijgaarden; Eliane M S Leyten; Nathalie M Delfos; David J Hetem; Jos Kerremans; Mieke Zwarts; Sandra Cozijn; Tom H M Ottenhoff; Simone A Joosten; Sandra M Arend
Journal:  Eur Respir J       Date:  2022-08-10       Impact factor: 33.795

4.  Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Assunta Navarra; Valentina Vanini; Gilda Cuzzi; Claudia Cimaglia; Luigi Ruffo Codecasa; Carmela Pinnetti; Niccolò Riccardi; Fabrizio Palmieri; Andrea Antinori; Delia Goletti
Journal:  J Infect       Date:  2020-02-22       Impact factor: 6.072
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.